XML 26 R15.htm IDEA: XBRL DOCUMENT
v3.26.1

Loss Per Common Share | 3 Months Ended
--- | ---
Mar. 31, 2026
Earnings Per Share [Abstract] |
Loss Per Common Share | Loss Per Common Share Basic and diluted loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is the same as basic net loss per common share for the three months ended March 31, 2026 and 2025, because the effect of adjusting the weighted average number of common shares outstanding during the period for the potential dilutive effect of common stock equivalents would be antidilutive due to the Company’s net loss position for these periods. The 515,754 shares of common stock underlying the outstanding March 2025 Pre-Funded Warrants, the 1,538,461 shares of common stock underlying the outstanding July 2025 Pre-Funded Warrants, and the 682,921 shares of common stock underlying the outstanding January 2026 Pre-Funded Warrants have been included in the weighted-average number of shares of common stock used to calculate net loss per share, basic and diluted, attributable to common stockholders because the shares may be issued for little or no consideration, they are fully vested, and the March 2025 Pre-Funded Warrants, the July 2025 Pre-Funded Warrants, and the January 2026 Pre-Funded Warrants are immediately exercisable upon their issuance date. The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
| As of March 31, 2026:
| 2026 |  | 2025
Anti-dilutive common stock equivalents: |
October 2024 Common Warrants | 2,398,414 |  | 2,398,414 |
March 2025 Common Warrants | 8,316,882 |  | 8,316,882 |
July 2025 Common Warrants | 3,076,921 |  | — |
January 2026 Series A Common Warrants | 26,926,675 |  | — |
January 2026 Series B Common Warrants | 26,926,675 |  | — |
January 2026 Series C Common Warrants | 26,926,675 |  | — |
Stock options outstanding | 2,327,465 |  | 1,595,263
Unvested RSAs | — |  |  | 40,137
Unvested RSUs | 148,350 |  | 330,500 |
Total anti-dilutive common stock equivalents | 97,048,057 |  | 12,681,196

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration